EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis

Xinyu Xiang, Xiaoli Yang, Mengyi Shen, Chen Huang, Yifeng Liu, Xiaoli Fan iD, Li Yang iD

Canadian Journal of Gastroenterology and Hepatology · 2021-01 · 2021 (1)

DOI: 10.1155/2021/6691425 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 21.01.2021. Verfasst von Xinyu Xiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hos…. Hauptthemen laut MEDLINE: Cholangitis, Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the response between the current recommended dosage 13–15 mg/kg/d and 20 mg/kg/d dose of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) patients who do not respond completely to a standard dose of UDCA.

Methods

We included 73 patients with poor response and randomized them into two groups to investigate whether increasing the dosage of UDCA was beneficial to nonresponders. Patients assigned to the 13–15 mg/kg/d group continued with standard therapy, and participants in the 18–22 mg/kg/d group switched to the higher dosage (18–22 mg/kg/d), with a follow‐up of 12 months for both groups. The primary endpoints were the rate of response at 6 months and drug side effects.

Results

According to the Paris 2 criteria, patients receiving 18–22 mg/kg/d UDCA achieved a response rate of 59.4% compared with 36.1% in the standard dosage group ( P = 0.046) at 6 months, respectively. At 12 months, the high‐UDCA‐dosage group achieved a response rate of 59.4% compared with 47.2% in the standard dosage group ( P = 0.295), respectively. Additionally, the risk score predicted by the UK‐PBC model was lower in high‐dosage UDCA‐treated patients than in the standard dosage group (all P < 0.05). Side effects include diarrhea, nausea and vomiting, rash, and newly developed high blood pressure, which were mild and tolerated.

Conclusions

Patients treated with the high UDCA dosage showed some advantages over those who continued the standard dosage in terms of biochemical remission and disease progression, indicating that standard therapy with UDCA for 6 months and then another 1 year with high UDCA dosage for nonresponders could be a treatment option before second‐line therapy is recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangitisLiver Cirrhosis, BiliaryCholagogues and CholereticsDisease ProgressionHumansTreatment OutcomeUrsodeoxycholic Acid

Substanzen

Cholagogues and CholereticsUrsodeoxycholic Acid

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

ORCID-Profile: Xiaoli Fan, Li Yang

Förderung

  • West China Hospital, Sichuan University

Zitieren

APA

Xiang, X., Yang, X., Shen, M., Huang, C., Liu, Y., Fan, X., & Yang, L. (2021). Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology, 2021(1). https://doi.org/10.1155/2021/6691425

Vancouver

Xiang X, Yang X, Shen M, Huang C, Liu Y, Fan X, et al. Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology. 2021;2021(1). doi:10.1155/2021/6691425

BibTeX
@article{Xiang2021,
  author = {Xiang, Xinyu and Yang, Xiaoli and Shen, Mengyi and Huang, Chen and Liu, Yifeng and Fan, Xiaoli and Yang, Li},
  title = {Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis},
  journal = {Canadian Journal of Gastroenterology and Hepatology},
  year = {2021},
  volume = {2021},
  number = {1},
  doi = {10.1155/2021/6691425}
}
Kostenlos starten →